Genetic and physiological data implicating the new human gene G72 and the gene for <scp>d</scp> -amino acid oxidase in schizophrenia
-
- Ilya Chumakov
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Marta Blumenfeld
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Oxana Guerassimenko
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Laurent Cavarec
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Marta Palicio
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Hadi Abderrahim
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Lydie Bougueleret
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Caroline Barry
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Hiroaki Tanaka
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Philippe La Rosa
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Anne Puech
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Nadia Tahri
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Annick Cohen-Akenine
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Sylvain Delabrosse
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Sébastien Lissarrague
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Françoise-Pascaline Picard
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Karelle Maurice
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Laurent Essioux
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Philippe Millasseau
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Pascale Grel
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Virginie Debailleul
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Anne-Marie Simon
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Dominique Caterina
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Isabelle Dufaure
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Kattayoun Malekzadeh
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Maria Belova
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Jian-Jian Luan
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Michel Bouillot
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Jean-Luc Sambucy
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Gwenael Primas
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Martial Saumier
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Nadia Boubkiri
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Sandrine Martin-Saumier
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Myriam Nasroune
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Hélène Peixoto
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Arnaud Delaye
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Virginie Pinchot
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Mariam Bastucci
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Sophie Guillou
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Magali Chevillon
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Ricardo Sainz-Fuertes
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Said Meguenni
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Joan Aurich-Costa
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Dorra Cherif
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Anne Gimalac
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Cornelia Van Duijn
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Denis Gauvreau
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Gail Ouelette
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Isabel Fortier
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- John Realson
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Tatiana Sherbatich
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Nadejda Riazanskaia
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Evgeny Rogaev
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Peter Raeymaekers
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Jeroen Aerssens
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Frank Konings
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Walter Luyten
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Fabio Macciardi
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Pak C. Sham
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Richard E. Straub
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Daniel R. Weinberger
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Nadine Cohen
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
-
- Daniel Cohen
- Genset S.A., F-91030 Evry, France; Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium; Research Center of Mental Health, Academy of Medical Sciences, Moscow 113152, Russia; Signalgene Biotechnologies, Montreal, QC, Canada H2M 2NG; Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute of Psychiatry, London SE5 8AF, United Kingdom; and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892
抄録
<jats:p> A map of 191 single-nucleotide polymorphism (SNPs) was built across a 5-Mb segment from chromosome 13q34 that has been genetically linked to schizophrenia. DNA from 213 schizophrenic patients and 241 normal individuals from Canada were genotyped with this marker set. Two 1,400- and 65-kb regions contained markers associated with the disease. Two markers from the 65-kb region were also found to be associated to schizophrenia in a Russian sample. Two overlapping genes G72 and G30 transcribed in brain were experimentally annotated in this 65-kb region. Transfection experiments point to the existence of a 153-aa protein coded by the G72 gene. This protein is rapidly evolving in primates, is localized to endoplasmic reticulum/Golgi in transfected cells, is able to form multimers and specifically binds to carbohydrates. Yeast two-hybrid experiments with the G72 protein identified the enzyme <jats:sc>d</jats:sc> -amino acid oxidase (DAAO) as an interacting partner. DAAO is expressed in human brain where it oxidizes <jats:sc>d</jats:sc> -serine, a potent activator of <jats:italic>N</jats:italic> -methyl-D-aspartate type glutamate receptor. The interaction between G72 and DAAO was confirmed <jats:italic>in vitro</jats:italic> and resulted in activation of DAAO. Four SNP markers from DAAO were found to be associated with schizophrenia in the Canadian samples. Logistic regression revealed genetic interaction between associated SNPs in vicinity of two genes. The association of both DAAO and a new gene G72 from 13q34 with schizophrenia together with activation of DAAO activity by a G72 protein product points to the involvement of this <jats:italic>N</jats:italic> -methyl- <jats:sc>d</jats:sc> -aspartate receptor regulation pathway in schizophrenia. </jats:p>
収録刊行物
-
- Proceedings of the National Academy of Sciences
-
Proceedings of the National Academy of Sciences 99 (21), 13675-13680, 2002-10-03
Proceedings of the National Academy of Sciences
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1361699996339813888
-
- NII論文ID
- 80015618218
-
- ISSN
- 10916490
- 00278424
- http://id.crossref.org/issn/00278424
-
- データソース種別
-
- Crossref
- CiNii Articles